


- 3) A compound or pharmaceutically acceptable salt thereof, according to claim 1, wherein the compound is according to Formula III:



III

Wherein Cy, R⁴, R⁵, R^{6a}, R^{6b}, R⁷, R⁸ and the subscript a are according to claim 1.

- 4) A compound or pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein R⁵ is -CH₃, or -C₂H₅.
- 5) A compound or pharmaceutically acceptable salt thereof, according to claim 3, wherein R⁵ is -CH₂-CH₂-CN, -CH₂-CH₂-OH, -CH₂-CF₃, or -CH₂-CH₂-C(=O)NH₂.
- 6) A compound or pharmaceutically acceptable salt thereof, according to any one of claims 1-5, wherein Cy is 4-10 membered mono or bicyclic heterocycloalkyl containing one or more heteroatoms independently selected from O, N, and S.
- 7) A compound or pharmaceutically acceptable salt thereof, according to any one of claims 1-6, wherein the subscript a is 0.

-
- Chemical structures Va, Vb, Vc, and Vd are shown. Each structure is a pyrimidine-thiazole derivative. The pyrimidine ring has substituents R^{6a} and R^{6b}. The thiazole ring has a methyl group and a 4-fluorophenyl group. A side chain is attached to the thiazole ring. A group W₁ is attached to the side chain via a carbonyl group, which is further attached to a group G₁. The side chain is a 4-fluorophenyl group in Va and Vb, and a 4-fluorophenyl group in Vc and Vd.

- 9) A compound or pharmaceutically acceptable salt thereof, according to claim 8, wherein W_1 is $-CH_2-$, $-CH_2-CH_2-$, $-C(CH_3)H-$, $-CH_2-CH_2-CH_2-$ or $-CH_2-C(CH_3)H-$.
- 10) A compound or pharmaceutically acceptable salt thereof, according to any one of claims 8-9, wherein G_1 is 4-7 membered heterocycloalkyl containing one or more heteroatoms independently selected from O, N, and S, which heterocycloalkyl is substituted with one or two independently selected R^9 groups.
- 11) A compound or pharmaceutically acceptable salt thereof, according to claim 10, wherein R^9 is R^{10} and R^{10} is selected from OH, F, Cl, and $-CN$.
- 12) A compound or pharmaceutically acceptable salt thereof, according to any one of claims 1-11, wherein R^{6a} is H, $-CH_3$ or F, and R^{6b} is H.
- 13) A compound or pharmaceutically acceptable salt thereof, according to claim 1, wherein the compound is selected from:

(S)-2-((2-ethyl-6-(4-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile,

- tert-butyl 4-(3-((4-(4-chlorophenyl)thiazol-2-yl)(methyl)amino)-2-ethylimidazo[1,2-a]pyridin-6-yl)piperazine-1-carboxylate,
N-(6-(1-(cyclohexylmethyl)piperidin-4-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorophenyl)-N-methylthiazol-2-amine,
N-(2-ethyl-6-(5-methyl-4,5-dihydrooxazol-2-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorophenyl)-N-methylthiazol-2-amine,
N-(2-ethyl-6-(4-methyl-4,5-dihydrooxazol-2-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorophenyl)-N-methylthiazol-2-amine,
2-(2-ethyl-3-((4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)imidazo[1,2-a]pyridin-6-yl)-4,5-dihydrooxazole-4-carboxylic acid,
(2-(2-ethyl-3-((4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)imidazo[1,2-a]pyridin-6-yl)-4,5-dihydrooxazol-4-yl)methanol, and
4-(4-chlorophenyl)-N-(6-(4,5-dihydrooxazol-2-yl)-2-ethylimidazo[1,2-a]pyridin-3-yl)-N-methylthiazol-2-amine.
- 14) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to any one of claims 1-13.
 - 15) A pharmaceutical composition according to claim 14, comprising a further therapeutic agent.
 - 16) A compound or pharmaceutically acceptable salt thereof, according to any one of claims 1-13, or a pharmaceutical composition according to claim 14 or 15, for use in medicine.
 - 17) A compound or pharmaceutically acceptable salt thereof, according to any one of claims 1-13, or a pharmaceutical composition according to claim 14 or 15, for use in the treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases.
 - 18) A compound or pharmaceutically acceptable salt thereof or the pharmaceutical composition for use according to claim 17, wherein said compound or pharmaceutically acceptable salt thereof or pharmaceutical composition is administered in combination with a further therapeutic agent.
 - 19) The pharmaceutical composition according to claim 15, or the compound or pharmaceutically acceptable salt thereof or the pharmaceutical composition for use according to claim 18, wherein the further therapeutic agent is for the treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases.